Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Graduate Program in Immunology and Medical Scientist Training Program, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Howard Hughes Medical Institute, Baltimore, MD 21205, USA.
Immunity. 2018 May 15;48(5):872-895. doi: 10.1016/j.immuni.2018.04.030.
Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within weeks of treatment interruption. The major barrier to a cure is a small pool of resting memory CD4 T cells that harbor latent HIV-1 proviruses. This latent reservoir is now the focus of an intense international research effort. We describe how the reservoir is established, challenges involved in eliminating it, and pharmacologic and immunologic strategies for targeting this reservoir. The development of a successful cure strategy will most likely require understanding the mechanisms that maintain HIV-1 proviruses in a latent state and pathways that drive the proliferation of infected cells, which slows reservoir decay. In addition, a cure will require the development of effective immunologic approaches to eliminating infected cells. There is renewed optimism about the prospect of a cure, and the interventions discussed here could pave the way.
抗逆转录病毒疗法可以有效抑制 HIV-1 的复制,预防或逆转 HIV-1 感染者的免疫缺陷。然而,治疗中断后数周内病毒就会重新开始复制。治愈的主要障碍是一小部分静止的记忆 CD4 T 细胞,其中潜伏着 HIV-1 前病毒。目前,这个潜伏库是国际上激烈研究的焦点。我们描述了潜伏库是如何建立的,清除它所面临的挑战,以及针对该潜伏库的药物和免疫策略。成功开发出治愈策略很可能需要了解维持 HIV-1 前病毒处于潜伏状态的机制,以及驱动受感染细胞增殖的途径,这会减缓潜伏库的衰减。此外,治愈还需要开发有效的免疫方法来清除受感染的细胞。治愈的前景重新燃起了人们的希望,本文讨论的干预措施可能为此铺平了道路。